According to the latest update from CheckMate 227 Part 1, at 6 years’ minimum follow-up, nivolumab combined with ipilimumab continues to outperform chemotherapy up front for advanced non–small cell lung cancer in terms of overall survival. Dual immune checkpoint inhibition induced greater tumor shrinkage, and these deep responses strongly correlated with long-term OS benefit.

You do not currently have access to this content.